Hepcidin as a central mediator of anemia of chronic diseases associated with obesity;Anemia de las enfermedades crónicas asociada a obesidad: Papel de la hepcidina como mediador central

Revista Medica de Chile

Volumn 141, Issue 7, 2013, Pages 887-894

  Villarroel H , Pía ^a   Arredondo O , Miguel ^a   Olivares G , Manuel ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Anemia; Antimicrobial cationic peptides; Chronic disease; Obesity; Refractory

Indexed keywords

HEPCIDIN;

BLOOD; CHRONIC DISEASE; HOMEOSTASIS; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; METABOLISM; OBESITY; REVIEW;

ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; HEPCIDINS; HOMEOSTASIS; HUMANS; INFLAMMATION; OBESITY;

EID: 84889636489     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/S0034-98872013000700008     Document Type: Review

References (65)

1. Roy C. Anemia of Inflammation. Hematology Am Soc Hematol Educ Program 2010; 2010: 276-80.
2. Zafon C, Lecube A, Simó R. Iron in obesity. An ancient micronutrient for a modern disease. Obes Rev 2010; 11: 322-8.
3. Sanad M, Osman M, Gharib A. Obesity modulate serum hepcidin and treatment outcome of iron deficiency anemia in children: A case control study. Ital J Pediatr 2011; 37: 34.
4. Wenzel BJ, Stults HB, Mayer J. Hypoferraemia in obese adolescents. Lancet 1962; 2: 327-8.
5. Menzie CM, Yanoff LB, Denkinger BI, Mchugh T, Sebring NG, Calis KA, et al. Obesity related hypoferremia is not explained by differences in reported intake of heme and nonheme iron or intake of dietary factors that can affect iron absorption. J Am Diet Assoc 2008; 108: 145-8.
6. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8.
7. Nicolas G, Bennoun, M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci 2001; 98: 8780-5.
8. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2011; 276: 7806-10.
9. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfidebonded human peptide, exhibits antimicrobial activity. FEBS 2000; 480: 147-50.
10. Ganz T, Nemeth E. Hepcidin and Disorders of Iron Metabolism. Annu Rev Med 2011; 62: 347-60.
11. Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine hepcidin assay by mass spectrometry. Blood 2005; 106: 3268-70.
12. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131: 788-96.
13. Robson KJ. Hepcidin and its role in iron absorption. Gut 2004; 53: 617-9.
14. Valore E, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 2008; 40: 132-8.
15. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-9.
16. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidina. Proc Natl Acad Sci USA 2002; 99: 4596-601.
17. Wallace DF, Summerville L, Crampton EM, Frazer DM, Anderson GJ, Subramaniam VN. Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology 2009; 50: 1992-2000.
18. Truksa J, Lee P, Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 2009, 113: 688-95.
19. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531-9.
20. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood 2003; 101: 2461-3.
21. Stoian I, Manolescu B, Atanasiu V, Lupescu O, Buşu C Rom J. IL-6-STAT-3-hepcidin: linking inflammation to the iron metabolism. Intern Med 2007; 45: 305-9.
22. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007; 109: 353.
23. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metabolism 2005; 1: 191-200.
24. Nemeth, E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010; 2010: 750643.
25. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010; 120: 2395-405.
26. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006; 46: 554-7.
27. Laftah AH, Ramesh B, Simpson RJ, Solanky N, Bahram S, Schümann K, et al. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004; 103: 3940-4.
28. Pinhas-Hamiel O, Newfield RS, Koren I, Agmon A, Lilos P, Phillip M. Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int J Obes Relat Metab Disord 2003; 27: 416-8.
29. Ausk KJ, Ioannou GN. Is obesity associated with anemia of chronic disease? A population-based study. Obesity 2008; 16: 2356-61.
30. Lecube A, Carrera A, Losada E, Hernández C, Simo R, Mesa J. Iron deficiency in obese postmenopausal women. Obesity 2006; 14: 1724-30.
31. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes, Trends Immunol 2004; 25: 4-7.
32. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808.
33. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005; 184: 285-93.
34. Hintze KJ, Snow D, Nabor D, Timbimboo H. Adipocyte hypoxia increases hepatocyte hepcidin expression. Biol Trace Elem Res 2010; 143: 764-71.
35. Luciani N, Brasse-Lagnel C, Poli M, Anty R, Lesueur C, Cormont M, et al. Hemojuvelin: a new link between obesity and iron homeostasis. Obesity 2011; 19: 1545-51.
36. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
37. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-8.
38. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoinmune diseases. Autoimmun Rev 2007; 6: 457-63.
39. Iwasaki T, Nakajima A, Yoneda M, Yamada Y, Mukasa K, Fujita K, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005; 28: 2486-91.
40. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008; 582: 97-105.
41. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986; 261: 8708-11.
42. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003; 325: 332-9.
43. McCarty MF. Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxia-inducible factor-1α. Med Hypotheses 2003; 61: 567-73.
44. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
45. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-8.
46. Ahima RS, Prabakaran D, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-37.
47. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA 1996; 93: 8374-8.
48. Chung B, Matak P, McKie AT, Sharp P. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr 2007; 137: 2366-70.
49. del Giudice EM, Santoro N, Amato A, Brienza C, Calabrò P, Wiegerinck ET, et al. Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J Clin Endocrinol Metab 2009; 94: 5102-7.
50. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. ACRP30/adiponectin; adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-9.
51. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Lung Cell Mol Physiol 2007; 293: E1118-E1128.
52. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
53. Price EA, Schrier SL. Unexplained aspects of anemia of inflammation. Adv Hematol 2010; 2010: 508739.
54. Skikne BS. Serum transferrin receptor. Am J Hematol 2008; 83: 872-5.
55. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113: 5277-8.
56. Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol 2011; 154: 289-300.
57. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2008; 18: 319-32.
58. Zimmermann MB. Methods to assess iron and iodine status. Br J Nutr 2008; 99: S2-S9.
59. Verga Falzacappa MV, Casanovas G, Hentze MW, Muckenthaler MU. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med 2008; 86: 531-40.
60. Collins JF, Wessling-Resnick M, Knutson MD. Hepcidin regulation of iron transport. J Nutr 2008; 138: 2284-8.
61. Hugman A. Hepcidin: an important new regulator of iron homeostasis. Clin Lab Haematol 2006; 28: 75-83.
62. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011; 2011: 538-42.
63. Weiss, G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009; 1790: 682-93.
64. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation Blood 2007; 109: 4038-44.
65. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012; 87: 392-400.